Brain Edema Pipeline Reviewed for Global Markets in H1 2016 Report

Friday, July 1, 2016 Indian Health News
Email Print This Page Comment bookmark
Font : A-A+

PUNE, India, July 1, 2016 /PRNewswire/ -- adds "Brain Edema - Pipeline Review, H1 2016" market

research report complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for Brain Edema and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Brain Edema with 18 market data tables and 12 figures, spread across 44 pages is available at .

The report also reviews key players involved in the therapeutic development for Brain Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Brain Edema Pipeline Review, H1 2016 report include FibroGen, Inc., Pharmazz, Inc. and Remedy Pharmaceuticals, Inc. Drug profiles discussed in this research report includes AER-271, Drugs to Modulate Aquaporin Channels for Brain Edema and Cancer, FG-4497, glyburide, PMZ-2123 and Small Molecules to Block Aquaporin-4 for Brain Edema.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Brain Edema and reviews pipeline therapeutics for Brain Edema by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Brain Edema therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Brain Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Brain Edema.

Order a copy of Brain Edema - Pipeline Review, H1 2016 market research report @ .

Reasons to buy 

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Brain Edema
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Brain Edema pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Another newly published market research report titled on Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H1 2016 talks about companies involved in therapeutics development including Applied Genetic Technologies Corporation, bluebird bio, Inc., Minoryx Therapeutics s.l., ReceptoPharm, Inc. and Viking Therapeutics, Inc. Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Pipeline market research report of 48 pages is available at .

Explore more reports on Neurology therapeutics.

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact: Ritesh Tiwari UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune - 411013 Maharashtra, India. Tel:  +1-888-391-5441

Connect with Us:  G+ / Google Plus: Twitter: Facebook: RSS / Feeds:

SOURCE RnR Market Research

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store